TP53 and adenocarcinoma: As shown in Fig. 4A–G, a significant correlation was established between Livin gene expression and clinicopathological features, including age (41–60, 61–80, and 81–100 years), gender (male and female), histological subtype (adenocarcinoma), individual cancer stages (1, 2, and 3), nodal metastasis status (N0, N1, and N2), and TP53 mutation status (TP53-mutant and TP53-non-mutant), while no correlation was established in the promoter methylation level of Livin.